Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval by Yamamoto, Yutaka et al.
© 2011 Yamamoto et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
OncoTargets and Therapy 2011:4 123–136
OncoTargets and Therapy Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
123
Review
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/OTT.S13836
Nab-paclitaxel for the treatment of breast cancer: 
efficacy, safety, and approval
Yutaka Yamamoto1
ichiro Kawano2
Hirotaka iwase1
1Department of Breast and endocrine 
Surgery, Graduate School of Medical 
Sciences, Kumamoto University, 
Kumamoto, Japan; 2Department of 
Surgery, Asahino General Hospital, 
Kumamoto, Japan
Correspondence: Yutaka Yamamoto 
Department of Breast and endocrine 
Surgery, Graduate School of Medical 
Sciences, Kumamoto University,  
1-1-1 Honjo, Kumamoto,  
860-8556 Kumamoto, Japan 
Tel +81 096 373 5521 
Fax +81 096 373 5525 
email ys-yama@triton.ocn.ne.jp
Abstract: Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is a novel formulation of 
paclitaxel that does not require solvents such as polyoxyethylated castor oil and ethanol. Use 
of these solvents has been associated with toxic response, including hypersensitivity reactions 
and prolonged sensory neuropathy, as well as a negative impact in relation to the therapeutic 
index of paclitaxel. nab-paclitaxel displays greater antitumor activity and less toxicity than 
solvent-base paclitaxel. In a phase I trial of single nab-paclitaxel, the maximum tolerated dose 
was 300 mg/m2 with the dose limiting toxicities being sensory neuropathy, stomatitis, and 
superficial keratopathy. In the metastatic setting, a pivotal comparative randomized phase III 
study demonstrated that nab-paclitaxel (at 260 mg/m2 over 30 minutes infusion without pre-
medication every 3 weeks) mediated a superior objective response rate and prolonged time to 
progression compared with solvent-based paclitaxel (at 175 mg/m2 over a 3-hour injection with 
standard premedication). The nab-paclitaxel-treated group showed a higher incidence of sensory 
neuropathy than the solvent-based paclitaxel group. However, these adverse side effects rapidly 
resolved after interruption of treatment and dose reduction. Weekly administration of nab-
paclitaxel was also more active and displayed less toxicity compared with 100 mg/m2 docetaxel 
given triweekly. Nab-paclitaxel has already been approved in 42 countries for the treatment 
of metastatic breast cancer previously treated with anthracycline, based on confirmation of the 
efficacy and manageable toxicity in the metastatic setting. This review summarizes the most 
relevant knowledge on nab-paclitaxel for treating breast cancer in terms of clinical usefulness 
including efficacy and safety of this new agent.
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Introduction
Breast cancer in women is a major health problem worldwide, with approximately 
1,150,000 new cases diagnosed and 410,000 deaths attributed to the disease in 2002.1 
Breast cancer is a heterogeneous disease in terms of gene expression, morphology, clini-
cal course, and response to treatment. Gene expression profiling divides breast cancer 
into several subtypes including luminal, human epidermal growth factor receptor 2 
(HER2)-enriched, basal-like, and normal-like subtypes.2 Lumina A and B subtypes 
are also classified by expression levels of estrogen receptor (ER)-α and ER-α-related 
gene. Basal-like subtype is almost identical to triple-negative breast cancer which is 
defined as showing an absence of ER-α and progesterone receptor, and no protein 
overexpression or gene amplification of HER2. Luminal A subtype has better prognosis 
than luminal B, HER2-enriched and basal-like subtypes. Luminal and HER2-enriched 
subtypes have several effective therapeutic targets such as ER for endocrine therapy OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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and HER2 for anti-HER2 therapy. Basal-like subtype has 
no effective therapeutic target at present. The response for 
cytotoxic agents also different according to tumor subtypes. 
HER2-enriched and basal-like subtypes are more responsive 
to chemotherapy than the luminal A subtype.3
Chemotherapy for patients with breast cancer is effective 
in not only reducing recurrence of this disease and improv-
ing survival in the adjuvant setting, but also in prolonging 
survival and improving quality of life in the metastatic 
setting.
The taxanes, such as paclitaxel and docetaxel, are one of 
the most active and widely used classes of cytotoxic agents 
in breast cancer treatment. Taxanes act through binding with 
tubulin and stabilizing nonfunctional microtubule bundles, 
leading to subsequent defects in mitotic spindle assembly, 
chromosome segregation and cell division, resulting in 
cell death.4,5 A meta-analysis showed that the addition of 
taxane to an anthracycline-based regimen in the adjuvant 
setting improved the disease-free survival and overall 
survival (OS) in patients with high-risk early stage breast 
cancer compared with an anthracycline-based regimen.6 
Another meta-analysis in the metastatic setting showed 
that taxane and anthracycline were equivalent in terms of 
effects on response rate and OS, although the taxanes were 
significantly less efficacious than anthracyclines in relation 
to impact on progression-free survival (PFS).7 However, the 
conventionally used taxanes, paclitaxel and docetaxel, have 
several limitations for clinical use. For example, taxanes 
are poorly soluble in water due to hydrophobic properties, 
and they require solvents when used in clinical formulations. 
However, the use of solvents in the formulation of these 
therapeutic agents limits their clinical effectiveness, in that 
these vehicles induce toxic responses, such as hypersensitiv-
ity and peripheral neuropathy, and can reduce the extent of 
drug delivery to tumor.8
Nanoparticle albumin-bound paclitaxel (nab-paclitaxel, 
sold under the trade name Abraxane®; Celgene Corporation, 
Summit, NJ), which is a solvent-free form of paclitaxel, can 
potentially avoid these limitations. Nab-paclitaxel is widely 
approved for the treatment of metastatic breast cancer on the 
basis of results from pivotal trials showing that it has superior 
antitumor effects and improved tolerability than solvent-
based paclitaxel.9 In this review, we focus on discussing the 
clinical usefulness, safety, and efficacy of nab-paclitaxel. To 
achieve our aim, we searched papers on nab-paclitaxel for 
treating breast cancer electronically, by hand, and through 
discussion with experts. We mainly used PubMed (from 1970 
to 2011) to find published literature.
Development of nab-paclitaxel
Paclitaxel, a mitotic inhibitor which acts via microtubule 
stabilization, is isolated from the bark of the Pacific yew 
tree, Taxus brevifolia,10 and is widely used to treat sev-
eral solid tumor types including breast, lung, and ovarian 
cancer.
Paclitaxel is highly insoluble in water, with formulation 
of this agent requiring emulsification with solvents, such as 
polyoxyethylated castor oil (Cremophor EL®: CrEL) and 
ethanol, to allow intravenous administration.11 Furthermore, 
solvent-based paclitaxel must be diluted 5- to 20- fold with 
normal saline or 5% dextrose solutions before intravenous 
administration.12
The solvents used in paclitaxel formulation are biologi-
cally and pharmacologically active in that they can lead to 
serious toxicities such as hypersensitivity   reaction11 and 
peripheral neuropathy.13,14 CrEL promotes a plasticizer, 
di(2-ethylhexyl) phthalate (DEHP), which is released from 
standard intravenous tubing sets containing polyvinyl 
  chloride. Thus the infusional fluid can contain leached 
DEHP, which subsequently stimulates histamine release and 
results in hypersensitivity reaction, including   anaphylaxis. 
To   offset this adverse response, a special infusion set 
(containing nonpolyvinyl chloride tubing with an in-line 
filter) must be used with prolonged infusion, as well as 
premedication with corticosteroids, antihistamine, and 
H2-blocker, when administering CrEL-paclitaxel infusion. 
Despite these precautions, this side effect still occurs at the 
level of minor reactions, such as flushing and rush, in 40% 
of treated patients, with life-threatening metastatic disease 
in 3% of treated patients.15
CrEL-paclitaxel induces peripheral sensory and motor 
neuropathy. Indeed, peripheral neuropathy is a dose-  limiting 
factor for CrEL-paclitaxel, with the effect often being pro-
longed and irreversible. Such irreversible neuropathy is 
associated axonal degeneration, vesicular   degeneration, 
and demyelination.16,17 In addition, CrEL has been shown 
to have a negative effect in relation to the antitumor prop-
erties of paclitaxel. The formation of CrEL micelles in 
the plasma compartment entraps paclitaxel, resulting in 
reduced drug clearance, nonlinear pharmacokinetics, and 
free drug fraction.15,18
These findings are strongly associated with the absence of 
a dose-dependent antitumor response in breast cancer patients 
treated with paclitaxel.19 Several developments have taken 
place in efforts to avoid the above-mentioned disadvantages 
of solvent-based taxanes. Nab-paclitaxel, which is CrEL-free, 
is a key example of such efforts.OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
125
Nab-paclitaxel for breast cancer
The role of albumin as a drug 
delivery system and nab-paclitaxel
Albumin plays an important role in the delivery of hydropho-
bic molecules to target tissue. Albumin is a natural carrier 
of endogenous hydrophobic molecules such as vitamins, 
hormones, and other substances in the human circulation.20,21 
Albumin binds these substrates reversibly in a noncovalent 
manner. Albumin is also associated with endothelial tran-
scytosis of protein-bound and unbound plasma components 
through binding to a 60 kDa cell surface glycoprotein recep-
tor (gp60) on the endothelial cell membrane. gp60 induces 
caeolin-1, resulting in internalization of the albumin-substrate 
complex into caveola, transcytotic vesicles, with substrates 
being subsequently delivered into tumor cells.22–26
Nab-paclitaxel is prepared by high-pressure homogeniza-
tion of paclitaxel in the presence of serum albumin, resulting 
in a colloidal suspension comprising nanoparticles of 130 nm 
on average, which prevent the risk of capillary blockage 
after intravenous infusion.27,28 Nab-paclitaxel consists of 
a lyophilized powder, which is reconstituted with 20 mL 
0.9% sodium chloride solution before intravenous infusion. 
Each single-use vial contains 100 mg of paclitaxel and 
approximately 900 mg of human albumin. The final colloid 
solution contains 5 mg/mL of paclitaxel and approximately 
45 mg/mL of albumin. Based upon in vivo study, it seems 
that the nab particles disperse into the individual albumin 
molecules with bound paclitaxel immediately after introduc-
tion into aqueous solution, as would occur after injection into 
the bloodstream.8
Preclinical studies
Using athymic mice bearing human cancer xenografts, Desai 
et al demonstrated that the antitumor activity and toxicity 
profile of nab-paclitaxel was better than that of CrEL-
  paclitaxel.27 The lethal dose (LD)50 and maximum tolerated 
dose (MTD) for nab-paclitaxel and CrEL-paclitaxel were 47 
and 30 mg/kg/day and 30 and 13.4 mg/kg/day, respectively. 
At equitoxic doses, nab-paclitaxel had significantly better 
antitumor effects including tumor-free survival, time to tumor 
recurrence (P = 0.004), tumor doubling time (P = 0.0015), and 
tumor volume (P = 0.009) compared with CrEL-  paclitaxel. 
At an equal dose of paclitaxel, the level of intratumoral 
paclitaxel accumulation was higher in nab-paclitaxel-treated 
mice than those in receipt of CrEL-paclitaxel. The extent of 
endothelial binding and transcytosis of paclitaxel was signifi-
cantly greater for nab-paclitaxel than CrEL-paclitaxel, with 
this difference being completely suppressed by an inhibitor 
of caveola-mediated transcytosis. CrEL also suppressed 
paclitaxel binding to endothelial cells and albumin. These 
findings indicated that nab-paclitaxel mediates greater intra-
tumoral accumulation of paclitaxel and associated increased 
efficacy compared with CrEL-paclitaxel.
Pharmacokinetic study
The relevant pharmacokinetic parameters in several studies 
are shown in Table 1. In a phase I study of nab-paclitaxel 
administration over 30 minutes every 3 weeks in 19 patients 
with metastatic melanoma or breast cancer, the MTD 
was determined to be 300 mg/m2.28 The dose-limiting toxici-
ties (DLTs) were sensory neuropathy (3 patients), stomatitis 
(2 patients), and superficial keratopathy (2 patients). No hyper-
sensitivity reaction was observed despite no premedication 
such as corticosteroids and antihistamines. Nab-paclitaxel also 
showed linear pharmacokinetics. In more detail, plasma levels 
of paclitaxel declined in a biphasic manner after intravenous 
administration of nab-paclitaxel with a rapid first phase rep-
resenting distribution to the peripheral tissue and the second 
slower phase representative of drug elimination. Sparreboom 
et al performed a comparative pharmacokinetics study of 
nab-paclitaxel (260 mg/m2 given as a 30-minute infusion) and 
CrEL-paclitaxel (175 mg/m2 given as a 180-minute infusion) 
in patients with metastatic breast, lung, and ovarian cancer.29 
The maximum concentration of paclitaxel was 6.5-fold higher 
for nab-paclitaxel than for CrEL-paclitaxel. The mean area 
under the curve (AUC) from time zero to infinity and plasma 
terminal elimination rate for nab-paclitaxel was similar to 
that observed for CrEL-paclitaxel notwithstanding the differ-
ences in administration dose, resulting in similar elimination 
half-lives for paclitaxel in these two groups. However, the 
mean apparent total body clearance of the drug from plasma 
and the apparent volume of distribution during the terminal 
phase of paclitaxel after administration of nab-paclitaxel were 
both significantly higher than that seen after administration of 
CrEL-paclitaxel. This large volume of distribution (664 L/m2) 
for nab-paclitaxel suggests extensive extravascular distribution 
and/or tissue binding of paclitaxel.
Gardner et al also conducted a pharmacokinetic study 
of nab-paclitaxel (260 mg/m2 given as a 30-minute infu-
sion) compared with CrEL-paclitaxel (175 mg/m2 given 
as a 180-minute infusion).30 The mean fraction unbound of 
paclitaxel was significantly higher for nab-paclitaxel than 
CrEL-paclitaxel (0.063 ± 0.021 vs 0.024 ± 0.009; P , 0.001), 
although the total drug exposure was comparable between the 
two drug formulations. These findings are in agreement with 
the greater antitumor efficacy of nab-paclitaxel compared 
with that of CrEL-paclitaxel.OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Table 1 Pharmacokinetic parameters for nab-paclitaxel and CreL-paclitaxel
Authors Drug n Dose  
(mg/m2)
Infusion  
time (min.)
Cmax  
(ng/mL)
AUCinf  
(ng/h/mL)
t1/2 (h) CL  
(L/h/m2)
Vz (L/m2)
ibrahim et al28 nab-P 3 200 30 7757  
(35%)
9613  
(20%)
13.4  
(67%)
17.7  
(22%)
370  
(23%)
5 300 30 13520  
(7%)
17610  
(21%)
14.6  
(14%)
17.7  
(22%)
370  
(23%)
Nyman et al31 nab-P 6 100 30 4513  
(2002)*
4311  
(1557)*
18.2  
(3.0)*
25.7  
(8.3)*
667  
(209)*
3 150 30 8433  
(4816)*
7107  
(4231)*
14.8  
(2.74)*
27.4  
(16.9)*
617  
(432)*
Sparreboom et al29 nab-P 14 260 30 22969  
(113%)
14789  
(45%)
21.6  
(17.2%)
21.1  
(43.8%)
664  
(48%)
CreL-P 12 175 180 3543  
(57%)
12603  
(21%)
20.5  
(14.6%)
14.8  
(31.8%)
433  
(31%)
nab-P vs CrEL-P, P value ,0.001 0.524 0.479 0.048 0.040
Gardner et al30 nab-P 14 260 30 19556  
(36%)
20325  
(20%)
20.0  
(21.3%)
13.2  
(17.9%)
375  
(22%)
CreL-P 14 175 180 5128  
(33%)
20821  
(26%)
20.9  
(21.4%)
8.9  
(25.7%)
271  
(61%)
nab-P vs CrEL-P, P value ,0.00001 0.72 0.53 0.00002 0.003
Yamada et al32 nab-P 6 260 30 11635  
(13%)
14593  
(14%)
19.5  
(7.9)
18.1  
(12.9%)
510  
(19%)
Notes: The numerical values show mean and coefficient of variation; *standard deviation.
Abbreviations: n, number of patients; Cmax, maximum or peak concentration; AUCinf, area under the whole blood/plasma concentration-time curve from time 0 to time 
infinity; CL, total body clearance; Vz, volume of distribution; nab-P, nab-paclitaxel; CreL-P, Cremophor eL®-paclitaxel.
Another phase I study of nab-paclitaxel administration 
(30 minutes once a week for 3 weeks, followed by 1 week of 
rest) in 39 patients with advanced nonhematologic malignan-
cies was conducted.31 In this case, the dose of nab-paclitaxel 
ranged from 80 to 200 mg/m2. The MTDs for heavily and 
lightly pretreated patients were 100 mg/m2 and 150 mg/m2, 
respectively with the observed DLTs being grade 4 neu-
tropenia and grade 3 peripheral neuropathy, respectively. 
Pharmacokinetics were also linear over the dose range of 
80–200 mg/m2.
There was no ethnic difference in the pharmacokinetics 
of nab-paclitaxel between Westerners and Japanese.32
Clinical efficacy in metastatic 
setting
Single agent nab-paclitaxel
The tumor responses for single agent nab-paclitaxel in 
several clinical trials are shown in Table 2(a). Ibrahim et al 
conducted a phase II trial in 63 patients with metastatic breast 
cancer, who were treated with 300 mg/m2 nab-paclitaxel 
over 30 minutes every 3 weeks.33 Seventy-six percent of 
patients received prior chemotherapy, with 38% of patients 
having received such treatment in the metastatic setting. 
Overall response rates were 48% (95% CI, 35.3% to 60.0%) 
while the response rate in patients who had not received 
prior chemotherapy was 64% (95% CI, 49.0% to 79.2%). 
The median times to disease progression and median survival 
were 26.6 and 63.6 weeks, respectively.
Blum et al performed another phase II study of weekly 
nab-paclitaxel in patients with metastatic breast cancer, 
which had been heavily pretreated with taxanes.34 In total, 
181 patients were treated with either 100 mg/m2 (n = 106) 
or 125 mg/m2 (n = 75) nab-paclitaxel on days 1, 8, and 15, 
followed by 1 week of rest, every 28 days. The response 
rates of the 100 mg/m2 and 125 mg/m2 cohorts were 14% 
and 16%, respectively. The rates of disease control (objec-
tive response and stable disease $ 16 weeks) in these two 
cohorts were 26% and 37%, respectively. Median PFS and 
OS were also not significantly different between these two 
cohorts (100 mg/m2; PFS 3.0 months and OS 9.2 months, 
125 mg/m2; PFS 3.5 months and OS 9.1 months). Weekly 
administration of 100 mg/m2 nab-paclitaxel showed the same 
antitumor activity as 125 mg/m2, with the benefit of a more 
favorable toxicity profile in patients with metastatic disease 
that progressed after previous taxane treatment.
A pivotal international, randomized, open-label phase III 
trial was conducted to compare the activity and safety of 
nab-paclitaxel with CrEL-paclitaxel in metastatic breast 
cancer patients.9 Forty-six patients were randomized to nab-
paclitaxel (260 mg/m2 over a 30-minute infusion) without pre-
medication or CrEL-paclitaxel (175 mg/m2 over a 3-hour 
infusion) with standard premedication. Inclusion criteria OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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included no receipt of taxane for metastatic disease and no 
relapse with metastatic disease within 1 year of adjuvant 
taxane therapy. The objective response rate (ORR) and 
median time to progression (TTP) were significantly higher 
in nab-paclitaxel-treated patients than those receiving 
CrEL-paclitaxel (ORR: nab-paclitaxel 33% vs CrEL-
paclitaxel 19%; P = 0.001, TTP: nab-paclitaxel 23.0 weeks 
vs CrEL-paclitaxel 16.9 weeks; hazard ratio [HR] = 0.75, 
P = 0.001). Maximum responses occurred by cycle 3 in 
91% of responders in the nab-paclitaxel group and in 81% 
of responders in the CrEL-paclitaxel group. The OS in the 
nab-paclitaxel group was greater than that in CrEL-paclitaxel 
group (65.0 weeks vs 55.7 weeks, respectively), but this did 
not reach statistical significance (P = 0.374). This trial showed 
that nab-paclitaxel has superior clinical benefit including 
greater efficacy and a favorable safety profile without pre-
medication compared with CrEL-paclitaxel.
A randomized phase II study compared nab-paclitaxel 
administered triweekly and weekly with triweekly doc-
etaxel as first-line treatment for metastatic breast cancer.35 
Three-hundred and two patients were randomly assigned to 
300 mg/m2 nab-paclitaxel every 3 weeks, 100 mg/m2 weekly 
for 3 out of 4 weeks, 150 mg/m2 weekly for 3 out of 4 weeks, 
or docetaxel 100 mg/m2 every 3 weeks. Nab-paclitaxel, 
given as a weekly administration of 150 mg/m2, showed 
significantly greater PFS than 100 mg/m2 docetaxel given 
triweekly (12.9 vs 7.5 months, respectively; P = 0.0065). 
Weekly nab-paclitaxel, regardless of dose, demonstrated 
a greater ORR than docetaxel (nab-paclitaxel 100 mg/m2 
45%, 150 mg/m2 49%, docetaxel 35%), but this did not reach 
statistical significance. On the other hand, the disease control 
rate was significantly greater for patients treated with either 
dose of weekly nab-  paclitaxel compared with docetaxel 
(100 mg/m2 nab-paclitaxel 75%, 150 mg/m2 80%, docetaxel 
58%, 100 mg/m2 nab-paclitaxel vs docetaxel; P = 0.009, 
150 mg/m2 nab-paclitaxel vs docetaxel; P = 0.017). No differ-
ence between 300 mg/m2 nab-paclitaxel given triweekly, and 
docetaxel treatment, was observed in terms of PFS and OS. 
This trial in the first-line metastatic setting showed superior 
efficacy and safety for weekly, especially 150 mg/m2, nab-
paclitaxel compared with triweekly administered docetaxel.
Nab-paclitaxel in combination with cytotoxic agents
Tumor responses of nab-paclitaxel in combination with cyto-
toxic agents are listed in Table 2(b). Roy et al reported on a 
phase II trial of nab-paclitaxel and gemcitabine combination 
therapy in patients with previously untreated metastatic breast 
cancer.36 Fifty patients received 125 mg/m2 nab-paclitaxel 
and 1000 mg/m2 gemcitabine on days 1 and 8 every 21 days. 
The rates of complete response (CR) and partial response 
(PR) were 8% and 42%, respectively. The median PFS was 
7.9 months (95% CI 5.4 to 10 months), with PFS and OS at 
6 months being 60% (95% CI 48% to 76%) and 92% (95% 
CI 85% to 100%), respectively.
A phase II trial of nab-paclitaxel and capecitabine combi-
nation therapy in the first-line treatment of metastatic breast 
cancer has also been reported.37 In this case, 50 patients 
were treated with 125 mg/m2 nab-paclitaxel on days 1, 8, 
and 1650 mg/m2 capecitabine twice a day on days 1–14 
every 3 weeks. Of the 38 patients available for analysis of 
response, the ORR was 47.5%: PR rate was 39.5%, and the 
CR rate was 8%.
Nab-paclitaxel in combination  
with molecularly-targeted agents
Taxane in combination with molecularly targeted therapies, 
such as trastuzumab and bevacizumab, mediates a greater 
antitumor effect with acceptable toxicity profiles in the 
metastatic setting compared with taxane treatment alone. 
Antitumor effects of nab-paclitaxel in combination with 
molecular-targeted agents are shown in Table 2(c). The US 
Oncology Research Network conducted multi-institutional 
and open-label phase II trials for patients with HER2-negative 
metastatic breast cancer.38 Patients were treated with weekly 
125 mg/m2 nab-paclitaxel infusion over 30 minutes on days 
1, 8, and 15, and 10 mg/kg bevacizumab on day 1 of a 
28-day cycle as first-line chemotherapy. Of the 49 patients 
enrolled, 27 were evaluable for response. The confirmed ORR 
was 30% and the proportion of patients with stable disease 
.16 weeks was 22%. The median PFS was 9.2 months (95% 
CI, 5.3 to 16.1 months). Lobo et al also reported on a single-
center and open-label phase II study to examine the efficacy 
and safety of nab-paclitaxel, in combination with gemcit-
abine and bevacizumab, in the context of first-line therapy 
in patients with HER2-negative metastatic breast cancer.39 
Patients received 150 mg/m2 nab-paclitaxel, 1500 mg/m2 
gemcitabine, and 10 mg/kg bevacizumab on days 1 and 15 
of a 28-day cycle. Twenty-nine of the enrolled 30 patients 
were evaluable for antitumor response. The median PFS was 
10.4 months (95% CI: 5.6–15.2 months), with the ORR and 
clinical benefit rate being 75.9% and 93.1%, respectively. 
Conlin et al conducted an open-label, randomized phase II 
study of nab-paclitaxel in combination with bevacizumab 
as first-line chemotherapy for patients with HER2-negative 
metastatic breast cancer.40 Patients were randomly assigned 
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3 weeks (arm A), 260 mg/m2 nab-paclitaxel and 10 mg/kg 
bevacizumab every 2 weeks with figrastim (arm B), or 
130 mg/m2 nab-paclitaxel every week with 10 mg/kg bev-
acizumab every 2 weeks (arm C). Two-hundred and eight 
patients were randomized, with 202 patients administered the 
protocol treatment. There was no difference in ORR between 
these three groups (arm A: 42%, arm B: 42%, arm C: 41%). 
The median TTP was longer in arm C (9.2 months) than both 
arm B (6.4 months) and arm C (7.7 months, overall P = 0.028). 
Arm B was closed early due to an unacceptable toxicity pro-
file, with evidence of significantly more grade . 2 fatigue 
(arm A: 39%, arm B: 57%, arm C: 39%, P = 0.048) and bone 
pain (arm A: 10%, arm B: 19%, arm C: 4%, P = 0.024) as 
per the protocol-specified stopping rules. Although weekly 
nab-paclitaxel with bevacizumab for HER2-negative meta-
static breast cancer showed the highest therapeutic index, 
sensory neuropathy was limiting. These data suggest that 
an adequate weekly regimen for metastatic disease, such as 
a 3 week on and 1 week rest schedule, should be examined 
comparatively.
For HER2-positive metastatic breast cancer, Conlin et al 
also conducted a multicenter phase II study to evaluate the 
efficacy and safety of weekly nab-paclitaxel in combina-
tion with carboplatin and weekly trastuzumab as first-line 
  therapy.41 In this study, 33 patients were enrolled. Patients 
received 100 mg/m2 nab-paclitaxel in combination with 
carboplatin at AUC = 2 at days 1, 8, and 15 of a 28-day 
cycle (in the first set of 13 patients) or at AUC = 6 at day 1 
every 28 days (in the latter set of 19 patients). Trastuzumab 
was administered at 2 mg/kg weekly after a loading dose 
of 4 mg/kg. The ORR and clinical benefit rates (ORR and 
SD . 16 weeks) were 62.5% (95% CI 45.7% to 79.3%) 
and 81%, respectively. Nab-paclitaxel in combination 
with carboplatin and trastuzumab is highly active without 
increasing toxicities in breast cancer patients with HER2-
positive disease.
Mitrsching et al reported another phase II study of 
weekly 125 mg/m2 nab-paclitaxel with or without weekly 
trastuzumab in first-line chemotherapy.42 HER2-positive 
patients received trastuzumab concurrently. Seventy-two 
patients were enrolled in this study. Of 50 HER2-negative 
or unknown patients and 22 HER2-positive patients, 42 
and 21 patients were evaluable for tumor response. The 
objective response rates in HER2-negative or HER2-
positive patients were 38.1% and 52.4%, respectively. 
The overall benefits (CR + PR + SD) in patients with 
HER2-negative or HER2-positive patients were 66.7% 
and 71.4%, respectively.
in the adjuvant and neoadjuvant setting
Adjuvant chemotherapy deeply contributes prolongation of 
survival after standard local treatment. Standard adjuvant 
regimens are anthracycline-containing regimen and taxane. 
However, survival benefit form adjuvant chemotherapy is still 
limited and patients receiving chemotherapy suffer chronic 
toxicities such as anthracycline-related cardiomyopathy 
and taxane-induced peripheral neuropathy. Nab-paclitaxel 
is more effective and less toxic than conventional taxanes, 
CrEL-paclitaxel and docetaxel, in randomized trials for meta-
static breast cancer. Therefore, nab-paclitaxel is likely to be 
used in an adjuvant chemotherapy regimen. Several adjuvant 
trials of nab-paclitaxel have been conducted (Table 3).
Yardley et al conducted a pilot study in 62 patients with 
node positive or high-risk node-negative early-stage breast 
cancer, who received 4 cycles, at 21-day intervals, of nab-
paclitaxel (100 mg/m2 on days 1, 8, and 15) and cyclophos-
phamide (600 mg/m2 on day 1).43 HER2 positive patients also 
received trastuzumab 8 mg/kg intravenous on cycle 1 day 1, 
followed by 6 mg/kg every 21 days for a total of 52 weeks. 
Full doses of all agents were administered in .90% of 
cycles. Grade 3/4 neutropenia was observed in 53% of the 
patients; however, only one episode of febrile neutropenia was 
observed in a total of 249 cycles administered. Other grade 
3/4 toxicities (fatigue, nausea, vomiting, arthralgia/myalgia, 
peripheral neuropathy, and edema) were observed in less than 
5% of patients. This combination of weekly nab-paclitaxel and 
cyclophosphamide with or without trastuzumab is feasible and 
well tolerated in patients with early stage breast cancer.
Robert et al performed another pilot study of dose-dense 
doxorubicin plus cyclophosphamide followed by dose-dense 
nab-paclitaxel in patients with early breast cancer.44 In total, 
30 patients received 4 cycles of dose-dense doxorubicin 
60 mg/m2 plus cyclophosphamide 600 mg/m2 every 2 weeks 
with pegfilgrastim, followed by dose-dense 260 mg/m2 nab-
paclitaxel every 2 weeks (with pegfilgrastim given as needed). 
Twenty-nine of the 30 patients received nab-paclitaxel. Of 
the 29 patients, 27 (93.1%) patients received 4 cycles of 
nab-paclitaxel. Average and mean dose-intensity of nab-
paclitaxel was 120.3 mg/m2/week and 127.7 mg/m2/week, 
respectively. During nab-paclitaxel therapy, 10 (34%) 
patients were treated with pegfilgrastim; 27 patients (90%) 
experienced peripheral neuropathy. However, the percentage 
of patients having ,1 grade neuropathy at the end of treat-
ment, 2 and 8 months after treatment were 59%, 79%, and 
97%, respectively. Adjuvant dose-dense doxorubicin and 
cyclophosphamide followed by dose-dense nab-paclitaxel 
was feasible in patients with early breast cancer.OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Table 3 Adjuvant studies with nab-paclitaxel for breast cancer
Authors Study design  
and setting
Treatment schedule No. of  
pts.
Treatment received Toxicity
Yardley  
et al43
Pilot study 
Stage i–iii
nab-P 100 mg/m2  
(D1,8,15) + CPA  
600 mg/m2 (D1) q3w × 4  
if HeR2+, Tras  
8 → 6 mg/kg q3w × 52w
63 Discontinued nab-P/CPA: 2% 
nab-P omission: 15% 
nab-P reduction: 6%
Neutropenia: G3 37%, G4 16% 
Febrile neutropenia: G3 2% 
Fatigue: G3 5% 
Nausea: G3 2% 
Arthralgia/myalgias: G 2% 
Peripheral neuropathy:  
G2 7%, G3 2%
Robert  
et al44
Pilot study 
Stage i–iii
AC q2w × 4 → nab-P  
260 mg/m2 q2w + G-CSF
29 Discontinued nab-P: 7% 
Average elative dose  
intensity of nab-P: 92.5%
Neutropenia: G3 10%, G4 10% 
Febrile neutropenia: G3 0% 
Arthralgia/myalgias: G3 3% 
Peripheral neuropathy: G2 34%, G3 14%
McArthur  
et al45
Phase ii 
Stage i–iii 
HeR2–
AC q2w × 4 → nab-P  
260 mg/m2 q2w +  
G-CSF + Bev 10 mg/kg  
q2w × 8 → Bev  
15 mg/kg q3w × 8
80 withdraw before completion  
of treatment: 33%
Febrile neutropenia: G3 4% 
Fatigue: G3 10% 
Peripheral neuropathy: G2 24%, G3 14% 
Headache: G3 8% 
Hypertension: G3 18%, G4 1% 
Cellulitis/wound-healing complication:  
G3 8%
Abbreviations: nab-P, nab-paclitaxel; No., number; CPA, cyclophosphamide; Tras, trastuzumab; q3w, every 3 weeks; q2w, every 2 weeks; G, grade; AC, doxorubicin + 
cyclophosphamide; G-CSF, granulocyte-colony stimulating factor; Bev, bevacizumab; pts, patients.
McArthur et al reported on a feasibility study of beva-
cizumab plus dose-dense doxorubicin-cyclophosphamide 
followed by nab-paclitaxel in HER2-negative early-stage 
breast cancer.45 In this study, the authors evaluated the 
cardiac safety of bevacizumab plus dose-dense doxorubicin 
and cyclophosphamide followed by nab-paclitaxel. Eighty 
patients with normal left ventricular ejection fraction (LVEF) 
were enrolled. Baseline LVEF was 68%. LVEF at 2, 6, 9, and 
18 months after treatment initiation were 68%, 64%, 63%, 
and 66%, respectively. One patient developed symptomatic 
LV dysfunction at month 15. Common adverse events neces-
sitating treatment discontinuation were hypertension (4%), 
wound-healing complication (4%), and asymptomatic LVEF 
declines (4%). Bevacizumab with dose-dense doxorubicin 
and cyclophosphamide followed by nab-paclitaxel had a low 
rate of cardiac events.
These adjuvant studies mainly evaluated feasibility 
and tolerability of nab-paclitaxel in the adjuvant setting. 
  Prospective randomized trials are needed to determine the 
benefit of incorporating nab-paclitaxel rather than standard 
taxane formulations, such as solvent-based paclitaxel and 
docetaxel, in the adjuvant settings.
The purpose of neoadjuvant chemotherapy is to down-
stage locally advanced cancer to facilitate curative operation, 
as well as to introduce breast-conserving surgery for operable 
but large tumors. Several neoadjuvant trials of nab-paclitaxel 
have been performed for locally advanced and operable breast 
cancer (Table 4).
Robidoux et al demonstrated the safety and efficacy of 
nab-paclitaxel, followed by an anthracycline-containing regi-
men as neoadjuvant chemotherapy, for locally advanced breast 
cancer patients regardless of hormone receptor or HER2 
status.46 Sixty-six patients were enrolled, and 65 patients 
were analyzed in terms of response to this regimen. Patients 
received 100 mg/m2 of nab-paclitaxel weekly for 12 weeks and 
FEC (500 mg/m2 5-FU, 100 mg/m2 epirubicine, 500 mg/m2 
cyclophosphamide) every 21 days for 4 cycles. Patients 
with HER2-positive breast cancer received concomitant 
trastuzumab with nab-paclitaxel and FEC. When patients 
received trastuzumab, the epirubicin dose was reduced to 
75 mg/m2. The pathological complete response (pCR) rate 
in the breast was 29% (19 out of 65 patients). For the HER2-
positive subset, the pCR rate was 58% (11 out of 19 patients). 
This regimen was well tolerated without evidence of cardiac 
toxicity.
Yardley et al also showed the safety and efficacy of 
neoadjuvant dose-dense 3-drug combination therapy, 
nab-paclitaxel, epirubicin, and gemcitabine, together with 
pegfilgrastim support, for patients with locally advanced 
breast cancer.47 One hundred and twenty-three patients 
were enrolled, with 109 patients assessed in terms of tumor 
response. Patients received 6 doses of 2000 mg/m2 gemcit-
abine, 50 mg/m2 epirubicin, and 175 mg/m2 nab-paclitaxel, 
administered intravenously on day 1 every 14 days. 
  Following each chemotherapy dose, 6 mg pegfilgrastim was 
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Table 4 Neoadjuvant studies with nab-paclitaxel for breast cancer
Authors Study design  
and setting
Treatment schedule No. of pts. pCR  
(95% CI)
Other outcome
Paz et al53 Stage ii–iii Arm 1: TAC × 6 
Arm 2: AC q2w × 4 → CBDCA AUC 2 + nab-P  
125 mg/m2 (D1,8,15) q4w × 3 
Arm 3 (HeR2+): AC q2w × 4 → CBDCA AUC 2 +  
nab-P 125 mg/m2 (D1,8,15) q4w × 3 + tras qw × 12
15 
14 
 
10
7% 
7% 
 
40%
Yardley et al54 Phase ii 
Stage ii, iii
nab-P 100 mg/m2 (D1,8,15) + CBCDA AUC 6 q4w ×  
6 + Tras 4 → 2 mg/kg/w × 21 + Bev 5 mg/kg/w × 21
20 65%
Robidoux et al46 Phase ii 
Stage iiB–iiiB
nab-P 100 mg/m2 × 12 → FeC q3w × 4 
if Her2+, concomitant tras was used
46 (HeR2–) 
19 (HeR2–)
17% 
58%
2-year PFS: 81%  
(95% Ci, 70%–89%) 
2-years OS: 95%  
(95% Ci, 86%–98%)
Yardley et al47 Phase ii 
Stage i–iii
nab-P 175 mg/m2 + GeM 2000 mg/m2 + ePi 50 mg/m2 +  
G-CSF q2w × 6
116 20% ORR: 89% 
3-year PFS: 48% 
3-year OS: 86%
Kaklamani et al48 Stage i–iii 
HeR2+
nab-P 260 mg/m2 q3w + lapatinib 1000 mg/day 30 18% ORR: 83%
Abbreviations: AC, doxorubicin 60 mg/m2 + cyclophosphamide 600 mg/m2; TAC, docetaxel 75 mg/m2 + doxorubicin 50 mg/m2 + cyclophosphamide 500 mg/m2; FeC, 5FU 
500 mg/m2 + epirubicin 100 mg/m2 + CPA 600 mg/m2; nab-P, nab-paclitaxel; No., number; ORR, objective response rate; PFS, progression-free survival; OS, overall survival; 
CI, confidential interval; q3w, every 3 weeks; q4w, every 4 weeks; q2w, every 2 weeks; CBDCA, carboplatin; AUC, area under the curve; Tras, trastuzumab; EPI, epirubicin; 
G-CSF, granulocyte-colony stimulating factor; pts, patients.
20% (23 out of 109 patients), with the estimated 3-year PFS 
and OS being 48% and 86%, respectively. Overall, this form 
of neoadjuvant chemotherapy was well tolerated.
Kaklamani et al conducted an interesting pilot neoadju-
vant study in HER2-positive breast cancer which combined 
nab-paclitaxel and lapatinib, in an effort to avoid use of 
anthracycline, in patients with HER2-positive cancer.48 Thirty 
patients with stage I–III HER2-positive breast cancer were 
treated in the neoadjuvant setting with 1000 mg/day lapatinib 
and 260 mg/m2 nab-paclitaxel every 3 weeks for 4 cycles. 
The ORR, which was the primary endpoint of this study, and 
the pCR rate were 82.8% and 17.9%, respectively. There was 
no significant drop in the left ventricular ejection fraction. 
Indeed, this regimen was well tolerated. No predictive factor 
for response was found in this study.
The results of these neoadjuvant trials are also somewhat 
promising in the metastatic setting, although the evidence 
is still quite modest in this respect. Phase III studies com-
paring nab-paclitaxel-containing regimens with a standard 
neoadjuvant regimen are needed to determine wider utility 
in the clinical setting.
Safety
In a pivotal, randomized phase III trial in the metastatic set-
ting, the toxicity of single agent nab-paclitaxel (260 mg/m2 
every 3 weeks) was compared with that mediated by CrEL-
paclitaxel (175 mg/m2 every 3 weeks) and the data are 
presented in Table 5.9 Treatment compliance of both groups 
was equally high with 96% (nab-paclitaxel) or 94% (CrEL-
paclitaxel) of patients receiving 90% of the protocol-specified 
dose despite a higher dose-intensity of paclitaxel in the 
nab-paclitaxel group (85.1 mg/m2/week) than the CrEL-
paclitaxel group (57.02 mg/m2/week). Treatment discontinu-
ation, dose reduction and dose delay due to adverse events 
were also infrequent in both treatment groups. In addition, 
the safety profile of nab-paclitaxel was comparable to that 
of CrEL-paclitaxel although there were some differences 
between the two groups. Consistent with the safety data, no 
differences in quality of life (QOL) were observed between 
the two groups.
Grade 4 neutropenia was significantly lower in the nab-
paclitaxel group than in the CrEL-paclitaxel group (9% vs 
22%, respectively; P , 0.0001) in a randomized phase III 
trial. The mean nadir of neutrophils was also significantly 
higher in the nab-paclitaxel group than that observed 
in the CrEL-paclitaxel group (1.67 × 109 vs 1.31 × 109, 
  respectively; P = 0.046). These findings suggest that the 
CrEL vehicle may be responsible for the noted toxicity in 
patients treated with CrEL-paclitaxel. Febrile neutropenia 
was uncommon in both treatment groups, as was severe 
anemia and   thrombocytopenia. Hematologic toxicities were 
dose-dependent and reversible.
Hypersensitivity reactions, such as dyspnea, flushing, 
chest pain, hypotension, and arrhythmia, can occur during 
infusion of drugs. Almost all patients treated with nab-
paclitaxel received no premedication. On the other hand, OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
132
Yamamoto et al
Table 5 Frequency of important adverse events: nab-paclitaxel 260 mg/m2 versus CreL-paclitaxel 175 mg/m2
Adverse events Nab-paclitaxel (n = 229) CrEL-paclitaxel (n = 225)
All grade $Grade 3 All grade $Grade 3
Hematologic
  Neutropenia 80% 34% 82% 53%
  Thrombocytopenia 12% ,1% 15% ,1%
  Anemia 47% 1% 43% ,1%
  Febrile neutropenia 2% 2% 1% 1%
  infection 15% 4% 14% 2%
Nonhematologic
  Hypersensitivity reaction 4% 0% 12% 2%
  Sensory neuropathy 71% 10% 56% 2%
  Myalgia/arthralgia 44% 8% 49% 4%
  Asthenia 47% 8% 39% 3%
Gi toxicities
  Nausea 29% 3% 20% ,1%
  vomiting 16% 2% 8% ,1%
  Diarrhea 25% ,1% 13% ,1%
  Mucositis 15% 2% 12% ,1%
Fluid retention/edema 10% 0% 8% ,1%
injection site reaction ,1% 1%
Reprinted with permission. © 2008 American Society of Clinical Oncology.  All rights reserved. Gradishar wJ, Tjulandin S, Davidson N, et al. Phase iii trial of nanoparticle 
albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23(31):7794–7803.16
Abbreviations: CreL, Cremophor eL®; Gi, gastrointestinal.
almost all patients treated with CrEL-paclitaxel received 
premedication with corticosteroids and antihistamines to 
avoid hypersensitivity reaction. The incidence of this adverse 
event was low for both groups in the randomized trial. The 
incidence of severe hypersensitivity reaction was 2% in the 
CrEL-paclitaxel group despite their having received standard 
premedication.
Sensory neuropathy is a key toxic response in patients 
treated with paclitaxel. As expected, with a higher dose of 
paclitaxel, the incidence of a severe form of this toxic effect 
was greater in the nab-paclitaxel group than the CrEL-
  paclitaxel group (10% vs 2%, respectively; P , 0.001), 
as well as the overall incidence of this toxicity (71% vs 
56%,   respectively; P , 0.05), in the pivotal randomized 
comparative study. Fourteen out of 24 patients with severe 
sensory neuropathy in the nab-paclitaxel group improved 
after interruption of treatment in a median 22 days. Nab-
paclitaxel-induced peripheral neuropathy could be managed 
with treatment interruption and dose reduction. The incidence 
of persistent severe sensory toxicity by 28 days after the first 
occurrence was equal in both groups. The sensory neuropathy 
was cumulatively dose dependent and partially reversible.
The incidence of myalgia and arthralgia was of a medium 
level and almost the same in both groups. These toxicities 
were usually transient, occurred 2 or 3 days after nab-
paclitaxel administration, and resolved within a few days.49 
Medium-level asthenia was also evident in both groups, albeit 
with only a low frequency of severe symptoms observed. The 
incidence of gastrointestinal disorders and fluid retention was 
also low in both groups.
By comparison, examination of triweekly nab-paclitaxel 
(300 mg/m2) with weekly nab-paclitaxel (100 mg/m2 or 
150 mg/m2) and triweekly docetaxel (100 mg/m2) in a 
randomized phase II trial (Table 6) showed neutropenia 
occurring more frequently and in a more severe manner 
in patients who received docetaxel. In particular, grade 4 
neutropenia was significantly higher in patients treated 
with docetaxel (75%) compared with patients treated with 
nab-paclitaxel 100 mg/m2 qw, 150 mg/m2 qw, or 300 mg/m2 
q3w (5%, 9%, 5%, respectively; P , 0.001 for all three 
comparisons).
Consistent with these findings, the incidence of febrile 
neutropenia was significantly greater in the docetaxel group 
(8% vs 1% in each of the nab-paclitaxel groups). Among the 
three nab-paclitaxel groups, the incidence of all grades and 
grade 3 sensory neuropathy was higher in those groups with 
nab-paclitaxel 300 mg/m2 triweekly or 150 mg/m2 weekly 
compared with 100 mg/m2 weekly. However, the level of 
severe sensory neuropathy in the nab-paclitaxel groups 
reduced more rapidly than in the docetaxel group (median time 
to improvement in grade 3 sensory neuropathy; triweekly 300 
mg/m2 nab-paclitaxel was 22 days, weekly 150 mg/m2 nab-
paclitaxel was 19 days, weekly 100 mg/m2 nab-paclitaxel was 
22 days, and triweekly docetaxel 100 mg/m2 was 37 days).OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Table 6 Frequency of adverse events in .25% of patients in randomized phase ii trial: nab-paclitaxel 300 mg/m2 q3w vs nab-paclitaxel 
100 mg/m2 qw vs nab-paclitaxel 150 mg/m2 vs docetaxel 100 mg/m2 q3w
Adverse events Nab-paclitaxel  
300 mg/m2  
q3w (n = 76)
Nab-paclitaxel  
100 mg/m2  
qw (n = 76)
Nab-paclitaxel  
150 mg/m2  
qw (n = 74)
Docetaxel  
100 mg/m2  
q3w (n = 74)
Neutropenia
  All grade 93% 80% 91% 100%
  .Grade 3 44% 25% 44% 94%
Alopecia
  All grade 58% 76% 64% 71%
  .Grade 3 0% 0% 0% 0%
Sensory neuropathy
  All grade 73% 58% 68% 61%
  .Grade 3 17% 8% 14% 12%
Fatigue
  All grade 36% 34% 45% 55%
  .Grade 3 5% 0% 3% 19%
Arthralgia
  All grade 32% 19% 35% 22%
  .Grade 3 1% 0% 0% 0%
Reprinted with permission. © 2008 American Society of Clinical Oncology.  All rights reserved. Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer 
progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol. 2009;27(22):3611–3619.35
Abbreviations: q3w, every 3 weeks; qw, every week.
Fatigue was also more common and severe in the docetaxel 
group than in the nab-paclitaxel groups. The frequency of 
arthralgia was higher in patients with nab-paclitaxel given 
300 mg/m2 triweekly and nab-paclitaxel 150 mg/m2 given 
weekly compared with weekly nab-paclitaxel at 100 mg/m2 
and docetaxel. The frequency of severe toxicities was less 
in the weekly 100 mg/m2 nab-paclitaxel compared with tri-
weekly 300 mg/m2 nab-paclitaxel and the weekly 150 mg/m2 
nab-paclitaxel. Several studies in the adjuvant setting were 
conducted to evaluate the tolerability of the nab-paclitaxel-
containing regimen (Table 4). As a pilot study, Yardley et al 
reported adjuvant weekly nab-paclitaxel at 100 mg/m2 on 
days 1, 8, and 15 in combination with cyclophosphamide at 
600 mg/m2 on day 1 every 3 weeks. If HER2 positive, patients 
Table 7 Comparison between nab-paclitaxel and cremophor-
based paclitaxel
Nab-paclitaxel CrEL-paclitaxel
Premedication Unnecessary Necessary
In-line filter Unnecessary Necessary
Time of  
intravenous  
infusion
30 minutes weekly: 60 minutes 
Triweekly: 180 minutes
Administration  
dose
weekly: 100–150 mg/m2 
Triweekly: 260 mg/m2
weekly: 80–100 mg/m2 
Triweekly: 175 mg/m2
Administration  
for patients with  
hypersensitivity  
for alcohol
Possible impossible
Abbreviation: CreL: Cremophor eL®.
received triweekly trastuzumab. Sixty-two patients were 
enrolled in this adjuvant pilot study, which had a low rate of 
discontinuation and dose reduction for this treatment.47
Although dose-dense nab-paclitaxel and bevacizumab 
combination was not feasible in the metastatic setting, adju-
vant dose-dense doxorubicin and cyclophosphamide followed 
by nab-paclitaxel in combination with bevacizumab showed 
acceptable toxicity with low cardiac events.45 However, the 
discontinuation rate of this pilot study was not low (33%). 
Evaluation of safety and efficacy in the adjuvant setting is 
too limited. Large, randomized phase III studies to evaluate 
the efficacy and safety, especially long-term toxicity, of nab-
paclitaxel are needed.
Approval of nab-paclitaxel
Nab-paclitaxel was initially approved by the US Food and 
Drug Administration on 7th January 2005 and indicated for 
the treatment of breast cancer after failure of combination che-
motherapy for metastatic disease or relapse within 6 months 
of adjuvant chemotherapy, when prior therapy should have 
included an anthracycline unless clinically contraindicated. As 
of March 2011, nab-paclitaxel was approved in 42 countries 
including EU, Canada, India, and Japan.
Conclusion
Nab-technology can be used as an effective and novel 
drug delivery system: nab-paclitaxel (a nanoparticle-based 
formulation of paclitaxel encapsulated by albumin coating OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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instead of CrEL) has increased both the efficacy and safety 
of paclitaxel. Nab-paclitaxel has also several advantages over 
CrEL-paclitaxel, such as no need for premedication, special 
infusion set with in-line filter and alcohol, short infusion 
time, and high dose administration (Table 7). Nab-paclitaxel 
can improve the pharmacokinetic parameters of paclitaxel 
including the facilitation of dose-dependent linear pharma-
cokinetics, large volume of distribution, and large amount 
of free paclitaxel, thereby resulting in higher levels of drug 
delivery to the tumor compared with CrEL-paclitaxel. This is 
responsible for the increased antitumor effect. Clinical trials 
have demonstrated that single agent nab-paclitaxel displays 
high antitumor activity and manageable toxicity for patients 
with metastatic breast cancer. Phase I studies showed a higher 
MTD for nab-paclitaxel compared with CrEL-paclitaxel; 
the MTD of triweekly nab-paclitaxel was 300 mg/m2 and 
the MTD of weekly nab-paclitaxel in heavily and lightly pre-
treated patients was 100 mg/m2 and 150 mg/m2, respectively. 
The DLTs observed were sensory neuropathy, stomatitis, and 
superficial keratopathy in patients treated with nab-paclitaxel 
300 mg/m2 every 3 weeks. The pivotal randomized phase 
III trial showed that the ORR and time to progression in 
patients treated with nab-paclitaxel were significantly better 
than those treated with CrEL-paclitaxel. The OS in patients 
receiving nab-paclitaxel was apparently greater, albeit with no 
significant difference, than that seen with patients receiving 
CrEL-paclitaxel. The safety profile was almost comparable in 
both groups even though the administration dose of paclitaxel 
used was higher, without premedication. Sensory neuropathy 
was significantly greater in the nab-paclitaxel group than in 
the CrEL-paclitaxel. However, the recovery time for sensory 
neuropathy was shortened in the nab-paclitaxel group.
The antitumor effect of triweekly nab-paclitaxel 
(300 mg/m2) was similar to triweekly docetaxel (100 mg/m2). 
But the tolerability of nab-paclitaxel was favorable compared 
with that of triweekly docetaxel. Weekly nab-paclitaxel dis-
played superior antitumor effects and less toxicity compared 
with triweekly docetaxel. The optimal treatment schedule 
was not confirmed. However, the weekly regimen in terms 
of efficacy and tolerability may be better than the triweekly 
regimen, and CrEL-paclitaxel, for HER2-negative breast 
cancer based on the results of a randomized phase III trial.50 
Comparative phase III trials to determine the optimal treat-
ment schedule for nab-paclitaxel are warranted.
In the metastatic setting, nab-paclitaxel has already 
been used to increase the therapeutic index of paclitaxel 
compared with CrEL-paclitaxel. For example, in the 
Ribbon-1 trial, a bevacizumab-focused randomized study 
comparing   paclitaxel alone with paclitaxel in combination 
with bevacizumab for metastatic breast cancer as first-line 
chemotherapy, nab-paclitaxel was used for a control arm for 
standard paclitaxel.51 On the other hand, the data relating 
to nab-paclitaxel treatment in the adjuvant and neoadju-
vant settings have been limited even though preliminary 
results are promising. Therefore, the impact of prolonged 
recurrence-free and overall survival, as well as long-term 
toxicity, of a nab-paclitaxel-containing regimen has not 
been well elucidated. As nab-paclitaxel has higher efficacy 
and is well tolerated in the metastatic setting, prospective 
randomized trials of a nab-paclitaxel-containing regimen are 
urgently required to incorporate nab-paclitaxel rather than 
standard taxane, solvent-based paclitaxel and docetaxel, into 
the adjuvant and neoadjuvant settings.
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